| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3390648 | Rheumatic Disease Clinics of North America | 2008 | 7 Pages |
Abstract
Because of the role of the RhoA/Rho kinase (ROCK) pathway in regulating numerous pathologic processes including vasoconstriction, vascular remodeling, and fibrosis, ROCK inhibitors may be especially beneficial in treating Raynaud's phenomenon and scleroderma.
Related Topics
Health Sciences
Medicine and Dentistry
Immunology, Allergology and Rheumatology
Authors
Nicholas A. Flavahan,